Pharmaceutical

In the early stages of drug discovery, a drug candidate needs to be characterized for critical go or no go decision making.  The bottleneck in drug discovery process is the Adsorption, Distribution, Metabolism, Excretion and Toxicology (ADMET) evaluation within a living organism.  Therefore, technology increasing the analytical throughput for such analysis is essential in drug discovery.  By using the LDTD for ADMET studies, you will perform one analysis each 4 seconds increasing dramatically your throughput compared to your current LC-MS/MS method of analysis.  Moreover, many more applications can beneficiate from this analytical speed.

View how the LDTD can increase your Drugs discovery process

Application notes

• AN-0706 : High Throughput Analysis of 960 Reserpine Samples in 1.9 hours.

• AN-0708 : LDTD-MS/MS in 1.8 seconds with RSD of 2.4 % : Paracetamol in Human Plasma Crash.

• AN-0709 : Midazolam and 1-Hydroxymidazolam in Human Plasma : LDTD-MS/MS Analysis in 8 Seconds.

• AN-0710 : LDTD-MS/MS Analysis in 9 Seconds : Quantification of Mifepristone in Mouse Plasma.

• AN-0714 : High Throughput LDTD-MS/MS IC₅₀ Determination of CYP Inhibition in HLM.

Posters

• ASMS 2009 24 High Throughput LDTD-MS/MS IC50 Determination of CYP Inhibition in Human Liver Microsome (HLM).
• ASMS 2009 High Throughput Workflow for Midazolam and 1-Hydroxymidazolam Analysis in Human Plasma.
• ASMS 2008 Midazolam and 1-Hydroxymidazolam Determination in Human EDTA Plasma by LDTD/MS/MS in 8 seconds.
• ASMS 2008 High-Throughput Analysis of Mifepristone and Two Mifepristone Analogues in Mouse Heparin Plasma by LDTD-MS/MS in 9 seconds.
• ASMS 2007 High-Throughput LDTD-MS/MS Determination of Reserpine : 1000 Samples in less than 2 hours.

Posters produced by LDTD users

• IMSC 2009 Laser Diode Thermal Desorption (LDTD) Mass Spectrometry for High Throughput Analyses of Discovery DMPK In Vitro and In Vivo samples.
• ASMS 2009 Validation of Pioglitazone in Human Serum by Two Sample Introduction Methods : LDTD-APCI/MS/MS and LC-ESI/MS/MS.
• ASMS 2009 Application of LDTD-APCI-MS to Support Plasma Protein Bonding Study in Drug Discovery.

Posters produced in collaboration with LDTD users 

• ASMS 2009 LDTD-MS/MS Analysis of Eicosanoids and Other Mediators of Inflammation.
• ASMS 2009 Analysis of Fatty Acid Methyl Esters Using the High Throughput LDTD Source Coupled to the LTQ Orbitrap Mass Spectrometer. 
• ASMS 2008 Selected Ion Monitoring (SIM) Mode Data Collection Using the Laser Diode Thermal Desorption (LDTD) Source to Increase Sensitivity.
• ASMS 2008 Comparison of Laser Diode Thermal Desorption (LDTD) source vs LC-MS for the analysis of a therapeutic drug in biological extracts.
• ISSX 2008 Comparison of Various High Throughput Mass Spectrometry-based Technologies to Assess CYP Inhibitions.
• ASMS 2007 Application of a Laser Diode Thermal Desorption (LDTD) Ion Source for Mass Spectrometry in a Drug Discovery Environment.
• ASMS 2007 High Throughput Analysis of Testosterone in Human EDTA K2 Plasma.

Scientific Publication

• Analytical Chemistry 2007, 79(12), pp 4657-4665  High-throughput Cytochrome P450 Inhibition Assays Using Laser Diode Thermal Desorption-Atmospheric Pressure Chemical Ionization-Tandem Mass Spectrometry, Jin Wu, Christopher S. Hughes, Pierre Picard, Sylvain Letarte, Mireille Gaudreault, Jean-François Lévesque, Deborah A. Nicoll-Griffith, and Kevin P. Bateman DOI: 10.1021/ac070221o

NOTE

• The results published were obtained with a beta-LDTD ion source. Therefore, the laser patern reported should not be used with the current LDTD ion source. Moreover the CYP 1A2 should be run in negative mode. Please refer to the application note 0714 for updated operating conditions.